Please reference the list below for active Phase I/Translational clinical research being conducted by Comprehensive Cancer Centers. If a research offering is of interest, Email Us. Please add either the study number or details about the study in your email for a more fast and efficient response.

i2896 A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
i3189 A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer
i3194 A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors  **OPEN TO HRD+ ENDOMETRIAL**
i3209 A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
i3236 PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2-Targeted Therapy in Participants with Advanced Breast Cancer
i3294 A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients with Advanced Solid Tumor Malignancies.
i3257 A multicenter, open-label phase 1/1b dose-finding, safety, and
pharmacokinetic study of MBRC-101, an anti-Epha5 monomethyl auristatin E (MMAE) antibody drug conjugate, in advanced refractory solid tumors
i3316 A Phase 1, First in Human, Dose Escalation and Expansion, Multicenter Study of XMT1660 in Participants with Solid Tumors
i3324 A Multi-Center, Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of YL205 in Patients with Advanced Solid Tumors.
i3339 A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
i3351 A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants with Metastatic Solid Tumors
Independent A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Relapsed/Metastatic Solid Tumors.
Independent A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors
i3359 A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluatethe Safety, Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
i3362 A Phase 1b, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination with Toripalimab with or without Other Treatments in Participants with Advanced or Metastatic Solid Tumors.